URGN
NASDAQ
IL
UroGen Pharma Ltd. - Ordinary Shares
$18.82
▼ $-0.12
(-0.63%)
Vol 382K
6
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.1B
ROE
-204.5%
Margin
-170.6%
D/E
477.01
Beta
1.28
52W
$3–$30
Wall Street Consensus
14 analysts · Apr 20265
Strong Buy
7
Buy
2
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 25.0%
Next Report
May 11, 2026
EPS Estimate: $-0.51
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.51 | — | — |
| Dec 2025 | $-0.51 | $-0.54 | $-0.03 |
| Sep 2025 | $-0.71 | $-0.69 | +$0.02 |
| Jun 2025 | $-0.85 | $-1.05 | $-0.20 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -204.5% | -204.5% | -204.5% | -204.5% | -204.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -206.2% | -164.4% | -164.4% | -164.4% | -170.6% | -170.6% |
| Gross Margin | 85.3% | 88.5% | 88.5% | 88.5% | 88.0% | 88.0% |
| D/E Ratio | — | 477.01 | 477.01 | 477.01 | 477.01 | 477.01 |
| Current Ratio | 4.14 | 4.14 | 4.14 | 4.14 | 3.99 | 3.99 |
Key Ratios
ROA (TTM)
-71.0%
P/S (TTM)
11.36
P/B
25.4
EPS (TTM)
$-3.31
CF/Share
$-4.08
Rev Growth 3Y
+23.5%
52W High
$30.00
52W Low
$3.42
$3.42
52-Week Range
$30.00
How does URGN compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
URGN valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
11.4
▼
12%
below
peers
(12.9)
vs Peers
vs Industry
Fair value
P/B ratio
25.4
▲
932%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
URGN profitability vs Biotechnology peers
ROE
-204.5%
▼
204%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-170.6%
▲
41%
above
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
88.0%
▲
12%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-71.0%
▼
52%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
URGN financial health vs Biotechnology peers
D/E ratio
477.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
4.0
▼
10%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
1.3
▲
32%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
URGN fundamentals radar
URGN
Peer median
Industry
URGN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
URGN vs peers: key metrics
Latest News
No related news yet